Table 1.
Baseline characteristics of 13 EGFR mutation-positive patients with tumors other than NSCLC
| Age (years) | |
| Median | 57 |
| Range | 41–75 |
| Gender, n (%) | |
| Male | 9 (69.2) |
| Female | 4 (30.8) |
| Ethnicity, n (%) | |
| Caucasian | 12 (92.3) |
| Hispanic | 1 (7.7) |
| Tumor type [n/patients tested; (%)] | |
| Sarcoma | 2/38 (5.3) |
| Ovarian | 1/84 (1.2) |
| Head and neck: squamous cell | 1/61 (1.6) |
| Breast | 1/55 (1.8) |
| Skina | 1/24 (4.2) |
| Salivary glandb | 1/20 (5.0) |
| Cholangiocarcinoma | 1/20 (5.0) |
| Renal | 1/17 (5.9) |
| Adrenocortical | 1/10 (10.0) |
| Carcinoid | 1/8 (12.5) |
| Thymic | 1/7 (14.3) |
| Parathyroid | 1/1 (100.0) |
| EGFR mutation, n (%) | |
| Sensitive mutation | 2 (15.4) |
| Resistant mutation | 2 (15.4) |
| Sensitivity is unclear | 8 (61.5) |
| Two mutations | 1 (7.7) |
| KRAS mutation, n (%) | |
| Positive | 0 (0) |
| Negative | 12 (92.3) |
| Unknown | 1 (7.7) |
| PIK3CA mutation, n (%) | |
| Positive | 1 (7.7) |
| Negative | 11 (84.6) |
| Unknown | 1 (7.7) |
| TP53 mutation, n (%) | |
| Positive | 2 (15.4) |
| Unknown | 11 (84.6) |
| History of smoking, n (%) | |
| Ex-smoker | 4 (30.8) |
| Never | 9 (69.2) |
| Number of prior therapies | |
| Median | 3 |
| Range | 2–11 |
EGFR, epidermal growth factor receptor; KRAS, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NSCLC, non-small-cell lung cancer; PIK3CA, phosphatidylinositol-3-kinase, catalytic, alpha polypeptide; TP53, tumor protein p53.
aSkin: EGFR mutation-positive patient had basal cell carcinoma of the skin.
bSalivary gland: EGFR mutation-positive patient had parotid carcinoma.